Amgen Inc. — Sponsor Intelligence | 81 EU Trials

Filter these 81 trials by condition, phase, country and more.

Open in Search →

81 Registered trials

24 Recruiting

51 Completed trials

26 Countries active

74 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 42 Phase II: 12 Phase I/II: 4 Phase IV: 2 Phase I: 8 Phase I (Other): 9 Phase I (FiH): 3 Other: 1

Oversight events:

11 serious breaches 29 temporary halts 1 urgent safety measure 6 corrective measures across 16 trials

View oversight register →

100%

51 of 51 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 11 Small cell lung cancer extensive stage 7 Obesity 3 Overweight 3 Ductal adenocarcinoma of pancreas 3 Breast cancer 3 Gastric cancer 3 Prostate cancer 3 Ovarian cancer 2 Small cell lung cancer recurrent 2 Migraine 2 Osteogenesis imperfecta 2

Top IMPs

MARIDEBART CAFRAGLUTIDE 6 ROCATINLIMAB 6 TARLATAMAB 6 AMG 193 3 APREMILAST 3 BEMARITUZUMAB 3 AMG 732 2 BLINATUMOMAB 2 ERENUMAB 2 INEBILIZUMAB 2 OLPASIRAN 2 ROMIPLOSTIM 2

All trials — page 2

81 total

Apremilast Study in Children with Active Juvenile Psoriatic Arthritis Recruiting

2023-503435-17-00 Phase III 12 countries APREMILAST
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or… Recruiting

2023-507149-27-00 Phase III 5 countries ROMIPLOSTIM
Phase 3, Open-label Apremilast Pediatric Long-term Extension Study in Children with Oral Ulcers Associated With Behçet’s Disease or Juvenile… Recruiting

2023-503433-21-00 Phase III 3 countries APREMILAST
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL… Ended

2024-520050-38-00 Phase III 13 countries TARLATAMAB
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Phase III 15 countries OCRELIZUMAB
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moder… Ended

2025-520503-27-00 Phase I 1 country
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended

2024-516051-40-00 Phase II 6 countries TARLATAMAB
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT… Ended

2024-515523-11-00 Phase III 6 countries MARIDEBART CAFRAGLUTIDE
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA… Ended

2024-515524-36-00 Phase III 8 countries MARIDEBART CAFRAGLUTIDE
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended

2024-513968-25-00 Phase III 11 countries SILTUXIMAB; XALURITAMIG
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protoco… Ended

2024-511253-21-00 Phase I (Other) 9 countries
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mell… Ended

2024-513539-25-00 Phase II 8 countries MARIDEBART CAFRAGLUTIDE
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Phase III 16 countries TARLATAMAB
Apremilast study in children with active oral ulcers associated with Behçet's Disease Ended

2023-503436-40-00 Phase III 4 countries APREMILAST
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended

2024-510753-10-00 Phase III 15 countries ROCATINLIMAB
AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous… Ended

2024-511195-33-00 Phase I (Other) 8 countries
A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Ended

2023-508039-29-00 Phase II 5 countries ROCATINLIMAB
Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Ended

2023-509047-26-00 Phase I 4 countries
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm… Ended

2023-508359-38-00 Phase III 7 countries
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Phase III 12 countries NIVOLUMAB
EVOLVE-MI Ended

2023-509268-26-00 Phase IV 1 country
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Phase III 15 countries TARLATAMAB
A Phase 3, Open-label, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Chi… Ended

2023-503294-37-00 Phase III 9 countries ROMOSOZUMAB
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Phase III 17 countries

Showing 25–48 of 81 trials

← All sponsors A–Z